India Glycols Limited officially completed its corporate restructuring on September 1, 2026, dividing its operations into three distinct pure-play entities following approval from the National Company Law Tribunal Allahabad Bench. According to the regulatory filing submitted with the Registrar of Companies on September 1, 2026, the NCLT sanctioned the scheme on July 17, 2026.
The restructuring divides the conglomerate into India Glycols Limited, which retains the chemicals, glycols, bio-glycols, new specialty products, and industrial gases businesses; IGL Spirits Limited, which houses the spirits segment including Indian-made foreign liquor, country liquor, and bio-fuel; and Ennature Bio Pharma Limited, which holds the bio-pharma and bio-polymers portfolios.
Share Allotment Ratios and Record Date
Per the company's exchange filing, shareholders of India Glycols Limited on the record date of September 2, 2026, are entitled to receive one equity share of IGL Spirits Limited for every one equity share held in India Glycols Limited. Additionally, shareholders will receive one equity share of Ennature Bio Pharma Limited for every three equity shares held in the parent company.
While India Glycols Limited remains listed on both the Bombay Stock Exchange and the National Stock Exchange, the management of IGL Spirits Limited and Ennature Bio Pharma Limited will apply for separate listings on these exchanges. Specific dates for the independent listing of IGL Spirits Limited and Ennature Bio Pharma Limited on the BSE and NSE are not yet publicly available, according to the corporate disclosure.
Following the record date and post-demerger price adjustment, India Glycols shares experienced an over 79% fall in intraday trade on September 2, 2026, compared to the previous day closing price of ₹1,112.90 on September 1, 2026.
Financial Performance Across Segments
In the June 2026 quarter, the distinct business units reported separate financial metrics. India Glycols Limited for chemicals recorded net revenue of ₹345 crore, while IGL Spirits Limited reported net revenue of ₹694 crore, and Ennature Bio Pharma Limited posted net revenue of ₹90 crore.
On a consolidated basis, India Glycols reported a 32.18% year-on-year increase in net profit for Q1 FY27 to reach ₹96.83 crore. Consolidated revenue for the same period grew 19.39% year-on-year to ₹2,988.44 crore, according to the company financial statement.
Brokerage firm Arihant Capital highlighted that India Glycols is in a transformative and value-accretive phase, driven by the NCLT-approved demerger, which is expected to unlock shareholder value.
Addressing Conglomerate Discount Through Restructuring
The demerger strategy aims to address the conglomerate discount often applied to diversified companies, a pattern that has historically paid off in India by allowing each business to attract its own investors and management focus, according to comparative market assessments. This move mirrors other corporate restructurings designed to create pure-play investment vehicles, allowing for better capital allocation and market valuation for distinct business segments.
However, procedural delays in NCLT hearings earlier in May 2026 added short-term uncertainty for stakeholders, as noted by TipRanks.
Existing India Glycols shareholders will now hold shares in three distinct entities, potentially benefiting from a clearer valuation of each business segment and improved operational efficiency. The demerger is expected to allow each company management to concentrate more closely on respective growth opportunities and allocate resources according to specific business needs.
